|
|
Eli Lilly And Company (LLY) |
|
|
|
| |
LLY's Operating Income Growth by Quarter and Year
Eli Lilly And's Operating Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
Operating Income Growth Y/Y▼
|
Operating Income Growth Y/Y▼
|
| LLY Operating Income (in millions $) |
FY 2023 |
FY 2022 |
FY 2021 |
FY 2020 |
| IV Quarter |
December |
-
|
1,836.40
|
1,917.20
|
1,992.10
|
| III Quarter |
September |
-
|
1,676.50
|
1,881.20
|
1,278.30
|
| II Quarter |
June |
2,125.70
|
1,210.10
|
1,403.40
|
1,196.80
|
| I Quarter |
March |
1,494.00
|
2,404.30
|
1,155.30
|
1,590.80
|
| FY |
|
3,619.70
|
7,127.30
|
6,357.10
|
6,058.00
|
| LLY Operating Income second quarter 2023 Y/Y Growth Comment |
Eli Lilly And Company achieved in the second quarter 2023, above Company average Operating Income rise of 75.66% year on year, to $ 2,125.70 millions.
Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 12 other companies have achieved higher Operating Income growth. While Eli Lilly And Company' s Operating Income jump of 75.66% ranks overall at the positon no. 1181 in the second quarter 2023.
Explain Operating Income growth
|
| LLY Operating Income ( Y/Y Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
December |
- |
-4.21 % |
-3.76 % |
42.27 % |
| III Quarter |
September |
- |
-10.88 % |
47.16 % |
-10.65 % |
| II Quarter |
June |
75.66 % |
-13.77 % |
17.26 % |
-20.12 % |
| I Quarter |
March |
-37.86 % |
108.11 % |
-27.38 % |
146.6 % |
| FY |
|
- |
12.12 % |
4.94 % |
21.79 % |
LLY Operating Income (Quarter on Quarter Growth %) |
2023
|
2022 |
2021 |
2020 |
| IV Quarter |
December |
- |
9.54 % |
1.91 % |
55.84 % |
| III Quarter |
September |
- |
38.54 % |
34.05 % |
6.81 % |
| II Quarter |
June |
42.28 % |
-49.67 % |
21.47 % |
-24.77 % |
| I Quarter |
March |
-18.65 % |
25.41 % |
-42.01 % |
13.61 % |
| FY (Year on Year) |
|
- |
12.12 % |
4.94 % |
21.79 % |
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 458.23 % |
8.79 % |
-134.13 % |
| (Sep. 30. 2010) |
|
(Dec. 31, 2008) |
|
|
| Operating Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 458.23 % |
8.79 % |
-134.13 % |
| (Sep. 30. 2010) |
|
(Dec. 31, 2008) |
|
| Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023 |
Eli Lilly And's Q/Q Operating Income Growth
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 2642.73 % |
54.03 % |
-94.74 % |
| (Jun 30 2017) |
|
|
| LLY's II. Quarter Q/Q Operating Income Comment |
Eli Lilly And Company achieved in the II. Quarter 2023 below company average Operating Income jump of 42.28% quarter on quarter, to $ 2,125.70 millions.
Although the II. Quarter 2023 Eli Lilly And's performance was beneath the average of 54.03 %, this was still promising story, as the II. Quarter expension, eclipses the -49.67% surge in the II. Quarter a year ago
Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Operating Income quarter on quarter growth. While Eli Lilly And's Operating Income growth quarter on quarter, overall rank is 453. |
|
|
|
| Operating Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 2642.73 % |
54.03 % |
-94.74 % |
| (Jun 30 2017) |
|
|
| LLY's II. Quarter Q/Q Operating Income Comment |
Eli Lilly And Company achieved in the II. Quarter 2023 below company average Operating Income jump of 42.28% quarter on quarter, to $ 2,125.70 millions.
II. Quarter 2023 Eli Lilly And's Operating Income quarter on quarter growth appear to be paradoxical, even if below the ordinary rise of 54.03 %, yet it shows real recovery relative to the -49.67% in the same quarter a year ago Andrea Stewart, a business advisor situated in San Francisco mentioned.
Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Operating Income quarter on quarter growth. While Eli Lilly And's Operating Income growth quarter on quarter, overall rank is 453. |
|
Eli Lilly And's 12 Months Operating Income Growth Year on Year
Operating Income TTM Growth |
12 Months Ending
(Jun 30 2023) |
12 Months Ending
(Mar 31 2023) |
12 Months Ending
(Dec 31 2022) |
12 Months Ending
(Sep 30 2022) |
12 Months Ending
(Jun 30 2022) |
| Cumulative Operating Income 12 Months Ending |
$ 7,132.60 |
$ 6,217.00 |
$ 7,127.30 |
$ 7,208.10 |
$ 7,412.80 |
| Y / Y Operating Income Growth (TTM) |
-3.78 % |
-18.26 % |
12.12 % |
12.07 % |
27.17 % |
| Year on Year Operating Income Growth Overall
Ranking |
# 606 |
# 86 |
# 992 |
# 902 |
# 845 |
| Seqeuential Operating Income Change (TTM) |
14.73 % |
-12.77 % |
-1.12 % |
-2.76 % |
-2.54 % |
| Seq. Operating Income Growth (TTM) Overall
Ranking |
# 1181 |
# 769 |
# 1128 |
# 1496 |
# 1592 |
| Cumulative Operating Income growth
Comment |
Eli Lilly And showed decline, but improvement compare to trailing twelve month Operating Income decrease in Mar 31 2023. If the fiscal year would end in Jun 30 2023, Eli Lilly And's annual Operating Income decline would be -3.78% year on year to $7,133 millions.
Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 86 to 606. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
458.23 % |
8.79 % |
-134.13 % |
|
|
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
458.23 % |
8.79 % |
-134.13 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 13 |
| Sector |
# 53 |
| S&P 500 |
# 1181 |
|
| Cumulative Operating Income growth
Comment |
Eli Lilly And showed decline, but improvement compare to trailing twelve month Operating Income decrease in Mar 31 2023. If the fiscal year would end in Jun 30 2023, Eli Lilly And's annual Operating Income drop would be -3.78% year on year to $7,133 millions.
Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 86 to 606. |
| Operating Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
458.23 % |
8.79 % |
-134.13 % |
|
|
|
| Operating Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
458.23 % |
8.79 % |
-134.13 % |
|
|
|
| Operating Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 13 |
| Sector |
# 53 |
| S&P 500 |
# 1181 |
|
106.72%